Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL2401 SAD and MAD in Healthy Chinese Adult Participants
NCT07331545Phase 1Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Jan 2026
- Primary completion
- Jun 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) comparing QL2401 with Placebo (2 arms). Primary endpoint: Incidence and severity of adverse events at 57 days. Started Jan 2026; status: completed.
02
Drugs
QL2401
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on NCT07331545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07331545.